Arcellx, Inc. - Common Stock (NQ:ACLX)

115.07 UNCHANGED

Last Price Updated: 4:15 PM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

January 21, 2026

From Arcellx, Inc.

Via Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

December 06, 2025

From Arcellx, Inc.

Via Business Wire

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

4 Analysts Assess Arcellx: What You Need To Know ↗

July 31, 2025

Via Benzinga

(ACLX) - Analyzing Arcellx's Short Interest ↗

January 14, 2025

Via Benzinga

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

November 18, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Third Quarter 2025 Financial Results

November 05, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

November 03, 2025

From Arcellx, Inc.

Via Business Wire

In-Depth Examination Of 14 Analyst Recommendations For Arcellx ↗

December 09, 2024

Via Benzinga

14 Analysts Have This To Say About Arcellx ↗

December 09, 2024

Via Benzinga

Analyst Expectations For Arcellx's Future ↗

November 08, 2024

Via Benzinga

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

September 03, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx (ACLX) Q2 Revenue Drops 72% ↗

August 07, 2025

Via The Motley Fool

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

August 07, 2025

From Arcellx, Inc.

Via Business Wire

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 21, 2025

From Arcellx, Inc.

Via Business Wire

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗

May 21, 2025

Via Benzinga

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 14, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

May 08, 2025

From Arcellx, Inc.

Via Business Wire

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗

April 02, 2025

Via Benzinga

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

March 20, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

February 27, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

From Arcellx, Inc.

Via Business Wire

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗

February 12, 2025

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Via Benzinga

Arcellx Stock Earns 82 Relative Strength Rating ↗

December 27, 2024

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Via Investor's Business Daily

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗

December 09, 2024

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Via Investor's Business Daily

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗

December 09, 2024

Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.

Via Benzinga

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

December 08, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

November 07, 2024

From Arcellx, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.